文献速递糖尿病肥胖与代谢综合征

代谢功能障碍相关脂肪性肝病:异质性病理机制与基于代谢治疗的有效性

Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment.
PubMed 文献 · Lancet Diabetes Endocrinol · 2024-12-13

本文综述代谢功能障碍相关脂肪性肝病(MASLD)的异质性病理机制、结局及基于代谢治疗的反应差异。MASLD与心代谢疾病共享肥胖、胰岛素抵抗等病理机制,但各contributor存在显著异质性,影响疾病进展速度、与心代谢疾病的关系及治疗反应。减重是最有效的非药物治疗,但部分改善肝脏的药物不伴体重变化甚至体重增加,目前尚缺乏实施精准医学的充分证据。

要点

  • MASLD患者可进展为肝硬化和肝细胞癌,且2型糖尿病、心血管疾病、慢性肾脏病及肝外癌症风险增加。
  • 多数MASLD患者死于心脏相关原因,与MASLD和心代谢疾病共享病理机制有关。
  • 减重是最有效的非药物治疗方法,但部分改善肝脏的药物不伴体重变化甚至体重增加。

核心结论

  • 目前尚无足够证据将精准医学用于MASLD的风险预测、预防和治疗,但关于异质性的知识可能有助于未来实现这一目标。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • MASLD患者可进展为肝硬化和肝细胞癌,且2型糖尿病、心血管疾病、慢性肾脏病及肝外癌症风险增加。
  • 多数MASLD患者死于心脏相关原因,归因于MASLD与心代谢疾病共享的不健康饮食习惯、脂肪组织功能障碍、胰岛素抵抗和亚临床炎症等病理机制。
  • 脂肪变性和炎症的肝脏通过增加葡萄糖生成和释放促凝血因子、血脂异常及失调释放肝因子和microRNA影响血管和心脏。
  • MASLD病理生理contributor存在显著异质性,可能影响疾病进展速度、与心代谢疾病的关系及治疗反应。
  • 减重是最有效的非药物治疗方法;部分有效改善肝脏的药物不伴体重变化甚至体重增加,心代谢风险因素变化也观察到类似反应异质性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The global epidemic of metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing worldwide. People with MASLD can progress to cirrhosis and hepatocellular carcinoma and are at increased risk of developing type 2 diabetes, cardiovascular disease, chronic kidney disease, and extrahepatic cancers. Most people with MASLD die from cardiac-related causes. This outcome is attributed to the shared pathogenesis of MASLD and cardiometabolic diseases, involving unhealthy dietary habits, dysfunctional adipose tissue, insulin resistance, and subclinical inflammation. In addition, the steatotic and inflamed liver affects the vasculature and heart via increased glucose production and release of procoagulant factors, dyslipidaemia, and dysregulated release of hepatokines and microRNAs. However, there is substantial heterogeneity in the contributors to the pathophysiology of MASLD, which might influence its rate of progression, its relationship with cardiometabolic diseases, and the response to therapy. The most effective non-pharmacological treatment approaches for people with MASLD include weight loss. Paradoxically, some effective pharmacological approaches to improve liver health in people with MASLD are associated with no change in bodyweight or even with weight gain, and similar response heterogeneity has been observed for changes in cardiometabolic risk factors. In this Review, we address the heterogeneity of MASLD with respect to its pathogenesis, outcomes, and metabolism-based treatment responses. Although there is currently insufficient evidence for the implementation of precision medicine for risk prediction, prevention, and treatment of MASLD, we discuss whether knowledge about this heterogeneity might help achieving this goal in the future.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Stefan N, Yki-Järvinen H, Neuschwander-Tetri BA, et al. Metabolic dysfunction-associated steatotic liver disease: heterogeneous pathomechanisms and effectiveness of metabolism-based treatment. Lancet Diabetes Endocrinol. 2024. PMID: 39681121. doi:10.1016/S2213-8587(24)00318-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。